[Pathophysiology, clinical aspects and therapy of gastro-esophageal reflux disease].
The motility disturbances nd chemical factors which produces reflux oesophagitis and the findings which establish Barrett's oesophagus as a potential precancerous lesion are briefly reviewed. Controlled trials on the medical treatment of reflux oesophagitis are reported.
D000863:Antacids / Q000627:therapeutic use; D001471:Barrett Esophagus / Q000209:etiology; D002177:Candidiasis / Q000175:diagnosis; D002793:Cholic Acids / Q000009:adverse effects; D002927:Cimetidine / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004724:Endoscopy; D004941:Esophagitis / Q000209:etiology; D004943:Esophagogastric Junction / Q000502:physiology; D004947:Esophagus / Q000503:physiopathology*; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use; D011312:Pressure; D011374:Progesterone / Q000494:pharmacology
D000863:Antacids; D002793:Cholic Acids; D011374:Progesterone; D002927:Cimetidine; D008787:Metoclopramide
Pathophysiologie, Klinik und Therapie der gastro-ösophagealen Refluxkrankheit.